Avenue Therapeutics, Inc. (ATXI) Stock Price & Analysis

Avenue Therapeutics, Inc. (ATXI) closed at USD 0.39 on Friday, October 23, 2026, down 4.75% on the day. The US market is currently closed; this is not a live price.

The prior close was USD 0.4; the Oct 23, 2026 session ranged USD 0.39–0.39 on volume of 200 shares. Market capitalization is $1.27M, with a 52-week range of USD 0.15–0.97 (OID). Source: Nexqual, retrieved October 24, 2026 at 14:23 UTC.

Also available as compact Markdown for AI agents: nexqual.com/ATXI.md

Key facts (ATXI)

• Analysts: None.
• Total return with dividends: 1Y -45.8% vs S&P 500 +13.4%; 5Y -100.0% vs S&P 500 +76.9%.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (ATXI)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (ATXI)

P/B 2.2x · Earnings yield -218.91%

Analysts (ATXI)

Consensus None.

Total return (dividends reinvested) (ATXI)

ATXI suppliers, customers and competitors (named in its 10-K)

Quoted from the company's 10-K filed Mar 30, 2026.

Companies that name ATXI in their SEC reports

ATXI company outlook (results filed Nov 14, 2024)

• “EX-99.1 2 ex_748191.htm EXHIBIT 99.1 ex_748191.htm Exhibit 99.1 Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights - Topline data in Phase 1b/2a clinical trial of AJ201 for spinal and bulbar muscular atrophy anticipated around year-end 2024 Miami, FL – November 14, 2024 – Avenue Therapeutics, Inc.”

Quoted word-for-word from the SEC 8-K results press release.

ATXI analyst estimates and revisions

Key Statistics (as of October 24, 2026 at 14:23 UTC)

Technical Analysis (ATXI)

Nexqual's technical model rates ATXI "SELL" based on 1 bullish and 5 bearish signals across 127 daily candles, as of October 24, 2026 at 14:23 UTC.

Analyst Ratings (ATXI)

Wall Street analysts rate ATXI "None", per Nexqual as of October 24, 2026 at 14:23 UTC.

Earnings (ATXI)

Recent Earnings History

Source: Nexqual, October 24, 2026 at 14:23 UTC.

Financials & Fundamentals (ATXI)

Source: Nexqual, October 24, 2026 at 14:23 UTC.

Financial Health Score (ATXI)

Nexqual rates Avenue Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of October 24, 2026 at 14:23 UTC.

Ownership (ATXI)

Source: Nexqual, October 24, 2026 at 14:23 UTC.

Leadership (ATXI)

Avenue Therapeutics, Inc. is led by Alexandra MacLean, CEO & Director, per Nexqual as of October 24, 2026 at 14:23 UTC.

Major Backers & Investors (ATXI)

Notable institutional backers of Avenue Therapeutics, Inc. include Ikarian Capital, LLC, Boothbay Fund Management, LLC, according to Nexqual as of October 24, 2026 at 14:23 UTC.

Active Investors

Source: Nexqual, October 24, 2026 at 14:23 UTC.

From Avenue Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-30)

Key Strengths & Strategy (as disclosed to the SEC)

• In December 2019, we submitted a New Drug Application ("NDA") under the 505(b)(2) regulatory pathway for IV tramadol and received a Complete Response Letter (the "First CRL") from the FDA in October 2020.
• Investigational New Drug Application pertaining to IV tramadol, as well as all supporting documentation and relevant correspondence with the FDA.
• Our goal is to obtain, maintain and enforce patent protection for our proprietary technologies, including methods of treatment, to preserve our trade secrets, and to operate without infringing on the proprietary rights of other parties, both in the United States and in other countries.
• Our policy is to actively seek to obtain, where appropriate, the broadest intellectual property protection possible for our product candidates, proprietary information and proprietary technology through a combination of contractual arrangements and patents in the United States.

Partnerships

• In subsequent discussions with the FDA following our Complete Response Letters, we reached final agreement with the FDA in January 2024 on a final Phase 3 non-inferiority safety study designed to assess the theoretical risk of opioid-induced respiratory depression related to opioid stacking on IV tramadol compared to IV morphine.
• Effective as of February 17, 2015, Fortress obtained a worldwide (with the exception of Canada, Central America and South America with respect to 50 mg and 100 mg IV tramadol HCl injections) exclusive license to make, market and sell IV tramadol pursuant to an agreement with Revogenex, a privately held company in Dublin, Ireland, (the "Tramadol License Agreement").

Legal & Regulatory Risks (Item 1A, quoted)

• We may not receive regulatory approval for IV tramadol, or our approval may be significantly delayed due to scientific or regulatory reasons.
• The meeting on August 9, 2022 was a collaborative discussion on the study design and following the meeting, we incorporated the FDA's suggestions from the meeting minutes and submitted a detailed study protocol that could form the basis for the submission of a complete response to the Second CRL.
• Our current product candidate and any other product candidates we may license or acquire will also be subject to ongoing regulatory and compliance requirements, including regular inspections by the FDA and other regulatory authorities, following any such approval.
• The FDA, and/or other regulatory authorities, may also impose requirements for costly post-marketing studies or clinical trials and surveillance programs to monitor the safety or efficacy of the products.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 24, 2026 at 14:23 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt